Alberto M Pedroncelli
Overview
Explore the profile of Alberto M Pedroncelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fleseriu M, Pivonello R, Newell-Price J, Gadelha M, Biller B, Auchus R, et al.
Pituitary
. 2025 Jan;
28(1):22.
PMID: 39863744
Purpose: To evaluate the effect of osilodrostat and hypercortisolism control on blood pressure (BP) and glycemic control in patients with Cushing's disease. Methods: Pooled analysis of two Phase III osilodrostat...
2.
Newell-Price J, Fleseriu M, Pivonello R, Feelders R, Gadelha M, Lacroix A, et al.
J Endocr Soc
. 2024 Nov;
9(1):bvae201.
PMID: 39610378
Purpose: To assess whether simultaneous normalization of late-night salivary cortisol (LNSC) and mean urinary free cortisol (mUFC) in patients with Cushing disease treated with osilodrostat is associated with better clinical...
3.
Shimatsu A, Biller B, Fleseriu M, Pivonello R, Lee E, Leelawattana R, et al.
Endocr J
. 2024 Aug;
71(12):1103-1123.
PMID: 39183039
Cushing's disease is associated with increased morbidity and mortality. Osilodrostat, a potent oral 11β-hydroxylase inhibitor, provided rapid, sustained mean urinary free cortisol (mUFC) normalization in Cushing's disease patients in two...
4.
Feldt-Rasmussen U, Bolanowski M, Zhang S, Yu Y, Witek P, Kalra P, et al.
Front Endocrinol (Lausanne)
. 2024 Apr;
15:1250822.
PMID: 38577574
Introduction: Pasireotide, a somatostatin receptor ligand, is approved for treating acromegaly and Cushing's disease (CD). Hyperglycemia during treatment can occur because of the drug's mechanism of action, although treatment discontinuation...
5.
Johnsson M, Pedroncelli A, Hansson A, Tiberg F
Endocrine
. 2024 Feb;
84(3):1125-1134.
PMID: 38421556
Purpose: To assess the pharmacokinetics, pharmacodynamics, safety and tolerability of subcutaneous depot CAM4071, a novel, ready-to-use pasireotide formulation. Methods: This was a phase 1, randomised, open-label study in healthy volunteers....
6.
Feelders R, Fleseriu M, Kadioglu P, Bex M, Gonzalez-Devia D, Boguszewski C, et al.
Front Endocrinol (Lausanne)
. 2023 Oct;
14:1165681.
PMID: 37876540
Objective: This study evaluated short- and long-term efficacy and safety of the second-generation somatostatin receptor ligand pasireotide alone or in combination with dopamine agonist cabergoline in patients with Cushing's disease...
7.
Gadelha M, Snyder P, Witek P, Bex M, Belaya Z, Turcu A, et al.
Front Endocrinol (Lausanne)
. 2023 Sep;
14:1236465.
PMID: 37680892
Objective: To evaluate the long-term efficacy and safety of osilodrostat in patients with Cushing's disease. Methods: The multicenter, 48-week, Phase III LINC 4 clinical trial had an optional extension period...
8.
Fleseriu M, Biller B, Bertherat J, Young J, Hatipoglu B, Arnaldi G, et al.
Pituitary
. 2022 Oct;
25(6):959-970.
PMID: 36219274
Background: Many patients with Cushing's disease (CD) require long-term medical therapy to control their hypercortisolism. In the core phase of a Phase II study (LINC 2; NCT01331239), osilodrostat normalized mean...
9.
Fleseriu M, Newell-Price J, Pivonello R, Shimatsu A, Auchus R, Scaroni C, et al.
Eur J Endocrinol
. 2022 Aug;
187(4):531-541.
PMID: 35980235
Objective: To investigate the long-term efficacy and tolerability of osilodrostat, a potent oral 11β-hydroxylase inhibitor, for treating Cushing's disease (CD). Design/methods: A total of 137 adults with CD and mean...
10.
Gadelha M, Bex M, Feelders R, Heaney A, Auchus R, Gilis-Januszewska A, et al.
J Clin Endocrinol Metab
. 2022 Mar;
107(7):e2882-e2895.
PMID: 35325149
Context: Cushing disease, a chronic hypercortisolism disorder, is associated with considerable morbidity and mortality. Normalizing cortisol production is the primary treatment goal. Objective: We aimed to evaluate the safety and...